Secarna appoints Jens Holstein and Richard Mark Engelhard to new Advisory Board
Lucy Batizovsky | March 25, 2026 | Appointment | | Secarna Pharmaceuticals
Secarna Pharmaceuticals has appointed Jens Holstein and Richard Mark Engelhard to its new Advisory Board.
As part of the board, Holstein will act as a financial markets expert and Engelhard will be a shareholder representative.
The board was created to sustainably grow the business by providing strategic guidance, alongside financial and industry expertise.
Holstein bring over 30 years of leadership experience to the role, having previously been CFO of BioNTech. His past roles also include Regional CFO of Fresenius Kabi Asia Pacific, Managing Director at Fresenius ProServe and CFO of MorphoSys, a role he filled for almost ten years.
He currently serves as a non-executive member of Veracyte’s Board of Directors, as well as being Chairman of the Audit Committee.
Holstein said: “I look forward to contributing my financial and corporate strategy expertise in the life sciences, biotech and pharma environment to help guide sustainable growth and long-term value creation.”
Engelhard is currently General Manager of Engelhard Arzneimittel, a brand-name manufacturer in the OTC medicines segment.
Engelhard said: “Secarna’s recent development demonstrates the strength of its AI-empowered platform as well as it’s growing proprietary pipeline with SECN-15 as novel, potential best-in-class oligonucleotide in the field of oncology.
“I am pleased to join the Advisory Board and further support the management team as the Company continues to scale and execute on a compelling long-term growth and value-creation trajectory.
“Having supported Secarna for many years as a shareholder, I’m excited to now contribute in this expanded role.”
Related Content
Secarna Pharmaceuticals and Curie.Bio expand existing partnership
Secarna Pharmaceuticals has announced the expansion of the existing scientific and strategic collaboration agreement with …
Secarna and Vect-Horus collaborate to advance therapies for central nervous system disorders
Secarna Pharmaceuticals and Vect-Horus have announced that the companies will collaborate to develop RNA-targeted therapeutics …
Secarna Pharmaceuticals and Curie.Bio portfolio company enter research and option agreement
Global biopharma company, Secarna Pharmaceuticals, and biotech investor, Cure.Bio, have announced signing a research and …
